KIT gene mutations and patterns of protein expression in mucosal and acral melanoma

Journal of Cutaneous Medicine and Surgery

Volumn 16, Issue 2, 2012, Pages 135-142

  Abu Abed, Suzan ^a   Pennell, Nancy ^a   Petrella, Teresa ^a   Wright, Frances ^a   Seth, Arun ^a   Hanna, Wedad ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EOSIN; GENOMIC DNA; HEMATOXYLIN; STEM CELL FACTOR RECEPTOR;

ACRAL MELANOMA; ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CANCER LOCALIZATION; CASE STUDY; CONTROLLED STUDY; EXON; FEMALE; GENE; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC SCREENING; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIT GENE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUCOSAL MELANOMA; MUTATION RATE; MUTATIONAL ANALYSIS; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; EXONS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MELANOMA; MIDDLE AGED; MUCOUS MEMBRANE; MUTATION; NEOPLASM GRADING; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-KIT; SKIN NEOPLASMS;

EID: 84860324493     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2011.11064     Document Type: Article

References (49)

1. Chang AE, Karnell LH, Menck HR. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998;83:1664-78, doi:10.1002/(SICI)1097-0142(19981015)83: 8〈1664::AID-CNCR23〉3.0.CO;2-G. (Pubitemid 28465486)
2. McLaughlin CC, Wu XC, Jemal A, et al. Incidence of non-cutaneous melanomas in the U.S. Cancer 2005;103:1000-7, doi:10.1002/cncr.20866.
3. Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl Immunohistochem Mol Morphol 2005;13:205-20, doi:10.1097/01.pai.0000173054.83414. 22. (Pubitemid 41209013)
4. Singh M, Lin J, Hocker TL, et al. Genetics of melanoma tumorigenesis. Br J Dermatol 2008;158:15-21, doi:10.1111/j.1365-2133.2007.08316.x. (Pubitemid 350221925)
5. Takata M, Murata H, Saida T. Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma. Pigment Cell Melanoma Res 2010;23:64-71, doi:10.1111/j.1755- 148X.2009.00645.x.
6. Chabot B, Stephenson DA, Chapman VM, et al. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 1988;335:88-9, doi:10.1038/335088a0.
7. Huang E, Nocka K, Beier DR, et al. The hematopoietic growth factor KL is encoded by the Sl locus and is the ligand of the c-kit receptor, the gene product of the W locus. Cell 1990;63:225-33, doi:10.1016/0092-8674(90)90303-V.
8. Wehrle-Haller B. The role of Kit-ligand in melanocyte development and epidermal homeostasis. Pigment Cell Res 2003;16:287-96, doi:10.1034/j.1600-0749. 2003.00055.x. (Pubitemid 36597070)
9. Thomas I, Kihiczak GG, Fox MD, et al. Piebaldism: an update. Int J Dermatol 2004;43:716-9, doi:10.1111/j.1365-4632.2004.02114.x. (Pubitemid 39405852)
10. Grichnik JM, Burch JA, Burchette J, et al. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 1998;111:233-8, doi:10.1046/j.1523-1747.1998.00272.x. (Pubitemid 28354709)
11. Bastian BC, LeBoit PE, Hamm H, et al. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998;58:2170-5. (Pubitemid 28232904)
12. Alexis JB, Martinez AE, Lutzky J. An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. Melanoma Res 2005;15:283-5, doi:10.1097/00008390-200508000-00008. (Pubitemid 41127464)
13. Hofmann UB, Kauczok-Vetter CS, Houben R, et al. Overexpression of the KIT/SCF in uveal melanoma does not translate into clinical efficacy of imatinib mesylate. Clin Cancer Res 2009;15:324-9, doi:10.1158/1078-0432.CCR-08-2243.
14. Ivan D, Niveiro M, Diwan AH, et al. Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with imatinib mesylate (STI571, Gleevec). J Cutan Pathol 2006;33:280-5, doi:10.1111/j.0303-6987.2006. 00432.x.
15. Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br J Cancer 2005;92:1398-405, doi:10.1038/sj.bjc.6602529. (Pubitemid 40705006)
16. Wyman K, Atkins MB, Prieto V, et al. Multicenter phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006;106:2005-11, doi:10.1002/cncr.21834. (Pubitemid 43673217)
17. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353:2135-47, doi:10.1056/ NEJMoa050092. (Pubitemid 41653105)
18. Garrido MC, Bastian BC. KIT as a therapeutic target in melanoma. J Invest Dermatol 2010;130:20-7, doi:10.1038/jid.2009.334.
19. Rivera RS, Nagatsuka H, Gunduz M, et al. C-kit protein expression correlated with activating mutations in KIT gene in oral mucosal melanoma. Virchows Arch 2008;452:27-32, doi:10.1007/s00428-007-0524-2.
20. Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. J Am Acad Dermatol 2007;56:828-34, doi:10.1016/j.jaad.2006.06.017. (Pubitemid 46560994)
21. Thomas AJ, Erickson CA. The making of a melanocyte: the specification of melanoblasts from the neural crest. Pigment Cell Melanoma Res 2008;21:598-610, doi:10.1111/j.1755-148X.2008.00506.x.
22. Yoshida H, Nishikawa S, Okamura H, et al. The role of c-kit proto-oncogene during melanocyte development in mouse. In vivo approach by the in utero microinjection of anti-c-kit antibody. Dev Growth Differ 1993;35:209-220, doi:10.1111/j.1440-169X.1993.00209.x. (Pubitemid 23192011)
23. Ali S, Ali S. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). Gene 2007;401:38-45, doi:10.1016/j.gene.2007.06.017. (Pubitemid 47379512)
24. Zheng S, Chen LR, Wang HJ, et al. Analysis of mutation and expression of c-kit and PDGFR-alpha gene in gastrointestinal stromal tumor. Hepatogastroenterology 2007;54:2285-90.
25. Torres-Cabala CA, Wang WL, Trent J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. Mod Pathol 2009;22:1446-56, doi:10.1038/modpathol.2009.116.
26. Satzger I, Schaefer T, Kuettler U, et al. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer 2008;99:2065-9, doi:10.1038/sj.bjc.6604791.
27. Ashida A, Takata M, Murata H, et al. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas. Int J Cancer 2009;124:862-8, doi:10.1002/ijc.24048.
28. Antonescu CR, Busam KJ, Francone TD, et al. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer 2007;121:257-64, doi:10.1002/ijc.22681. (Pubitemid 46917693)
29. Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26:5360-7, doi:10.1200/JCO.2008.17.4284.
30. Hodi FS, Friedlander P, Corless CL, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol 2008;26:2046-51, doi:10.1200/JCO.2007.14.0707.
31. Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 2008;99:734-40, doi:10.1038/sj.bjc.6604482.
32. Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 2008;21:492-3, doi:10.1111/j.1755-148X.2008.00475.x. (Pubitemid 351990966)
33. Quintás-Cardama A, Lazar AJ, Woodman SE, et al. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 2008;5:737-40, doi:10.1038/ncponc1251.
34. Satzger I, Küttler U, Völker B, et al. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy - case report and review of the literature. Dermatology 2010;220:77-81, doi:10.1159/000265558.
35. Carvajal RD, Chapman PB, Wolchok JD, et al. A phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J Clin Oncol 2009;27(15 Suppl):9001.
36. Kluger HM, Dudek A, McCann C, et al. A phase II trial of dasatinib in advanced melanoma. J Clin Oncol 2009;27(15 Suppl):9010.
37. Zhu Y, Si L, Kong Y, et al. Response to sunitinib in Chinese KIT-mutated metastatic mucosal melanoma. J Clin Oncol 2009;27(15 Suppl):e20017.
38. Woodman SE, Trent JC, Stemke-Hale K, et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 2009;8:2079-85, doi:10.1158/1535-7163.MCT-09-0459.
39. Handolias D, Hamilton AL, Salemi R, et al. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 2010;102:1219-23, doi:10.1038/sj.bjc.6605635.
40. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011;305:2327-34, doi:10.1001/jama.2011.746.
41. Guo J, Si L, Kong Y, et al. Phase ii, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29:2904-9, doi:10.1200/JCO.2010.33.9275.
42. Lara PN, Redman MW, Kelly K, et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol 2008;26:463-7, doi:10.1200/JCO.2007.13.0344. (Pubitemid 351171700)
43. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340-6, doi:10.1200/JCO. 2006.06.2984. (Pubitemid 46630793)
44. Beadling C, Jacobson-Dunlop E, Hodi FS, et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008;14:6821-8, doi:10.1158/1078-0432.CCR-08-0575.
45. Kong Y, Si L, Zhu Y, et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin Cancer Res 2011;17:1684-91, doi:10.1158/1078-0432.CCR-10-2346.
46. Yun J, Lee J, Jang J, et al. KIT amplification and gene mutations in acral/mucosal melanoma in Korea. APMIS 2011;119:330-5, doi:10.1111/j.1600-0463. 2011.02737.x.
47. Todd AK, Haider SM, Parkinson GN, et al. Sequence occurrence and structural uniqueness of a G-quadruplex in the human c-kit promoter. Nucleic Acids Res 2007;35:5799-808, doi:10.1093/nar/gkm609. (Pubitemid 47506295)
48. Igoucheva O, Alexeev V. MicroRNA-dependent regulation of cKit in cutaneous melanoma. Biochem Biophys Res Commun 2009;379:790-4, doi:10.1016/j.bbrc.2008.12.152.
49. Godshalk SE, Paranjape T, Nallur S, et al. A variant in a microRNA complementary site in the 3′ UTR of the KIT oncogene increases risk of acral melanoma. Oncogene 2011;30:1542-5, doi:10.1038/onc.2010.536.